The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence-Reference-Cited by-同舟云学术

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Published:2022-10-19 Issue:1 Volume:16 Page:10-30
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Arnold Jonathon C.¹²³^ORCID,McCartney Danielle¹²⁴,Suraev Anastasia¹²⁴,McGregor Iain S.¹²⁴^ORCID

Affiliation:

1. Lambert Initiative for Cannabinoid Therapeutics The University of Sydney Sydney New South Wales Australia

2. Brain and Mind Centre The University of Sydney Sydney New South Wales Australia

3. Faculty of Medicine and Health, Discipline of Pharmacology, Sydney Pharmacy School The University of Sydney Sydney New South Wales Australia

4. Faculty of Science, School of Psychology The University of Sydney Sydney New South Wales Australia

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13425

Reference96 articles.

1. Cannabidiol (CBD) use in psychiatric disorders: A systematic review

2. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

3. A systematic review of cannabidiol dosing in clinical populations

4. Attitudes and knowledge of Australian gastroenterologists around use of medicinal cannabis for inflammatory bowel disease;Benson MJ;Crohn's Colitis 360,2020

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of cannabidiol and hemp extract on viability and function of hepatocytes derived from human induced pluripotent stem cells;Toxicology in Vitro;2024-12

2. The neurobehavioural effects of cannabidiol in alcohol use disorder: Study protocol for a double-blind, randomised, cross over, placebo-controlled trial;Contemporary Clinical Trials Communications;2024-10

3. FDA-approved cannabidiol [Epidiolex®] alleviates Gulf War Illness-linked cognitive and mood dysfunction, hyperalgesia, neuroinflammatory signaling, and declined neurogenesis;Military Medical Research;2024-08-22

4. Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts;Pain and Therapy;2024-08-03

5. From bench to bedside: the application of cannabidiol in glioma;Journal of Translational Medicine;2024-07-11